Table 4.
Health outcomes | Microbial measurements, odds ratio (95% confidence interval)
|
|
---|---|---|
Total culturable bacteria | Endotoxin | |
Two or more GD-like symptoms in the last 4 weeks | 0.8 (0.65–1.01)* | 0.8 (0.67–0.98)** |
Shortness of breath on exertion | 0.9 (0.78–1.03) | 0.9 (0.79–1.04) |
Fever and chills | 0.9 (0.72–1.19) | 0.8 (0.64–1.12) |
Flu-like achiness | 0.9 (0.78–1.02) | 0.9 (0.76–0.99)** |
Epidemiologically definedb asthma | 0.8 (0.71–1.00)** | 0.8 (0.67–0.96)** |
Wheeze in the last 4 weeks | 0.9 (0.81–1.07) | 0.9 (0.76–1.01)* |
Shortness of breath in the last 4 weeks | 0.9 (0.77–1.03) | 0.9 (0.80–1.05) |
Chest tightness in the last 4 weeks | 1.0 (0.81–1.13) | 0.9 (0.72–1.01)* |
Attack of cough | 1.0 (0.87–1.13) | 0.9 (0.79–1.03) |
Epidemiologically defined asthmab or airway hyper-responsivenessc | 0.8 (0.72–0.96)** | 0.8 (0.72–0.95)** |
Asthma-like symptoms included wheeze, attack of shortness of breath, chest tightness, attack of cough, or awakened by breathing difficulty.
Epidemiologically defined asthma included occupants who reported three or more asthma-like symptoms in the last 4 weeks or physician-diagnosed current asthma.
Nine more participants with airway hyper-responsiveness but who did not meet definition of epidemiologically defined asthma were added to the asthma outcome variable.
P-value ≤0.05;
0.05 < P-value <0.1.